Clinical Trial: NCT02104427
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | GPCR Therapeutics, Inc. |
| Information Provided By: | GPCR Therapeutics, Inc. |
| Last Update Posted: | 2021-04-19 |
Study Overview
Brief Summary
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Official Title
A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
Intervention / Treatment
- Drug: TG-0054 combined with G-CSF
Other Study ID Numbers
- TG-0054-04
Start Date
2015-02
Primary Completion Date (Actual)
2015-11
Study Completion Date (Actual)
2015-11
Enrollment (Actual)
12
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | GPCR Therapeutics, Inc. |
| Information Provided By: | GPCR Therapeutics, Inc. |
| Last Update Posted: | 2021-04-19 |
Study Overview
Brief Summary
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Official Title
A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
Intervention / Treatment
- Drug: TG-0054 combined with G-CSF
Other Study ID Numbers
- TG-0054-04
Start Date
2015-02
Primary Completion Date (Actual)
2015-11
Study Completion Date (Actual)
2015-11
Enrollment (Actual)
12
Study Type
Interventional
Phase
Phase 2